Funding boost gets Sunho Biologics over the IPO filing line
The cash-burning biotech has applied to list on the Hong Kong Stock Exchange after only barely achieving the minimum market value Key Takeaways: With no product or licensing revenue, Sunho…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
